328 related articles for article (PubMed ID: 12672070)
61. Differential binding of acapsulate and encapsulated strains of Cryptococcus neoformans to human neutrophils.
Richardson MD; White LJ; McKay IC; Shankland GS
J Med Vet Mycol; 1993; 31(3):189-99. PubMed ID: 8360810
[TBL] [Abstract][Full Text] [Related]
62. Immunosuppression, interleukin-10 synthesis and apoptosis are induced in rats inoculated with Cryptococcus neoformans glucuronoxylomannan.
Chiapello LS; Baronetti JL; Aoki MP; Gea S; Rubinstein H; Masih DT
Immunology; 2004 Nov; 113(3):392-400. PubMed ID: 15500627
[TBL] [Abstract][Full Text] [Related]
63. Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans.
McFadden DC; Fries BC; Wang F; Casadevall A
Eukaryot Cell; 2007 Aug; 6(8):1464-73. PubMed ID: 17601878
[TBL] [Abstract][Full Text] [Related]
64.
Colombo AC; Rella A; Normile T; Joffe LS; Tavares PM; de S Araújo GR; Frases S; Orner EP; Farnoud AM; Fries BC; Sheridan B; Nimrichter L; Rodrigues ML; Del Poeta M
mBio; 2019 Apr; 10(2):. PubMed ID: 30940711
[No Abstract] [Full Text] [Related]
65. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils.
Dong ZM; Murphy JW
J Clin Invest; 1996 Feb; 97(3):689-98. PubMed ID: 8609224
[TBL] [Abstract][Full Text] [Related]
66. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
Mukherjee S; Lee S; Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1994 Mar; 62(3):1079-88. PubMed ID: 8112842
[TBL] [Abstract][Full Text] [Related]
67. Catch me if you can: phagocytosis and killing avoidance by Cryptococcus neoformans.
García-Rodas R; Zaragoza O
FEMS Immunol Med Microbiol; 2012 Mar; 64(2):147-61. PubMed ID: 22029633
[TBL] [Abstract][Full Text] [Related]
68. Polysaccharide diversity in VNI isolates of Cryptococcus neoformans from Roraima, Northern Brazil.
Dal Pupo HD; Sena BAG; Reis FCG; Machado L; Fortes ST; de Almeida Junior JN; Godinho RMC; Rodrigues ML
Fungal Biol; 2019 Oct; 123(10):699-708. PubMed ID: 31542188
[TBL] [Abstract][Full Text] [Related]
69. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.
Maitta RW; Datta K; Lees A; Belouski SS; Pirofski LA
Infect Immun; 2004 Jan; 72(1):196-208. PubMed ID: 14688097
[TBL] [Abstract][Full Text] [Related]
70. Cryptococcal glucuronoxylomannan induces interleukin (IL)-8 production by human microglia but inhibits neutrophil migration toward IL-8.
Lipovsky MM; Gekker G; Hu S; Ehrlich LC; Hoepelman AI; Peterson PK
J Infect Dis; 1998 Jan; 177(1):260-3. PubMed ID: 9419203
[TBL] [Abstract][Full Text] [Related]
71. Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation.
Jalali Z; Ng L; Singh N; Pirofski LA
Clin Vaccine Immunol; 2006 Jul; 13(7):740-6. PubMed ID: 16829610
[TBL] [Abstract][Full Text] [Related]
72. A synthetic peptide as a novel anticryptococcal agent.
Cenci E; Bistoni F; Mencacci A; Perito S; Magliani W; Conti S; Polonelli L; Vecchiarelli A
Cell Microbiol; 2004 Oct; 6(10):953-61. PubMed ID: 15339270
[TBL] [Abstract][Full Text] [Related]
73. Binding of the wheat germ lectin to Cryptococcus neoformans chitooligomers affects multiple mechanisms required for fungal pathogenesis.
Fonseca FL; Guimarães AJ; Kmetzsch L; Dutra FF; Silva FD; Taborda CP; Araujo Gde S; Frases S; Staats CC; Bozza MT; Schrank A; Vainstein MH; Nimrichter L; Casadevall A; Rodrigues ML
Fungal Genet Biol; 2013 Nov; 60():64-73. PubMed ID: 23608320
[TBL] [Abstract][Full Text] [Related]
74. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.
Brandt S; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925
[TBL] [Abstract][Full Text] [Related]
75. Heat killed cells of Cryptococcus neoformans var. grubii induces protective immunity in rats: immunological and histopathological parameters.
Baronetti JL; Chiapello LS; Aoki MP; Gea S; Masih DT
Med Mycol; 2006 Sep; 44(6):493-504. PubMed ID: 16966166
[TBL] [Abstract][Full Text] [Related]
76. T-cell-dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A.
Sundstrom JB; Cherniak R
Infect Immun; 1993 Apr; 61(4):1340-5. PubMed ID: 8095924
[TBL] [Abstract][Full Text] [Related]
77. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat.
Goldman D; Lee SC; Casadevall A
Infect Immun; 1994 Nov; 62(11):4755-61. PubMed ID: 7927751
[TBL] [Abstract][Full Text] [Related]
78. Finite-element model of interaction between fungal polysaccharide and monoclonal antibody in the capsule of Cryptococcus neoformans.
Rakesh V; Schweitzer AD; Zaragoza O; Bryan R; Wong K; Datta A; Casadevall A; Dadachova E
J Phys Chem B; 2008 Jul; 112(29):8514-22. PubMed ID: 18588334
[TBL] [Abstract][Full Text] [Related]
79. Evasion of Innate Immune Responses by the Highly Virulent Cryptococcus gattii by Altering Capsule Glucuronoxylomannan Structure.
Urai M; Kaneko Y; Ueno K; Okubo Y; Aizawa T; Fukazawa H; Sugita T; Ohno H; Shibuya K; Kinjo Y; Miyazaki Y
Front Cell Infect Microbiol; 2015; 5():101. PubMed ID: 26779451
[TBL] [Abstract][Full Text] [Related]
80. Modulation of C5aR expression on human neutrophils by encapsulated and acapsular Cryptococcus neoformans.
Monari C; Kozel TR; Bistoni F; Vecchiarelli A
Infect Immun; 2002 Jul; 70(7):3363-70. PubMed ID: 12065474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
